News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24
Photo taken from Agenus/LinkedIn
Sep 15, 2024, 00:29

Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24

Agenus shared on LinkedIn:

“Breelyn Wilky, presented new data at ESMO24 highlighting the potential of our investigational immunotherapy combination, botensilimab and balstilimab, for treating patients with refractory sarcomas.

Learn more about this advancement.”

Source: Agenus/LinkedIn

Agenus Balstilimab botensilimab Breelyn Wilky cancer ESMO ESMO24 immunotherapy OncoDaily Oncology refractory sarcomas sarcomas
Special Coverage
Insight
Sep 15, 2024, 00:29
Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24
Insight
Sep 14, 2024, 19:28
Paolo Tarantino: Are all residual diseases equal?
Insight
Sep 14, 2024, 19:20
Elvina Almuradova: The future treatment landscape for hepatocellular carcinoma looks hopeful
Insight
Sep 14, 2024, 18:34
The first session of the City University of Hong Kong, AFCR symposium
Insight
Sep 14, 2024, 18:19
National Cancer Institute of Kenya has moved to a new location at NHIF Parking Complex
Insight
Sep 14, 2024, 18:10
We are extremely excited to be partnering with OncoDaily - Asian Fund for Cancer Research
Blog
Sep 14, 2024, 18:00
Rob Winn on lung health disparities at the ALC53
Blog
Sep 14, 2024, 17:49
Elvina Almuradova: Great opportunity to learn, network, and be inspired by cutting-edge research
Blog
Sep 14, 2024, 17:48
Beatrice Okumu: City Cancer Challenges' series of meetings in Nairobi
Insight
Sep 14, 2024, 17:48
May Daher: A novel NK immune evasion strategy in AML
Insight
Sep 14, 2024, 17:46
Kai Rejeski: Second Primary Malignancies following CAR T-cell therapy
Insight
Sep 14, 2024, 17:45
Jacob Adashek: Can Gilteritinib achieve a complete morphologic response in ALK-rearranged acute myeloid leukemia?